Aim: To evaluate the expression profile of vascular endothelial growth factor (VEGF), kinase-insert-domain-containing receptor (KDR) and p53 in patients from Northeastern China with transitional cell carcinoma (TCC) of bladder. Materials and Methods: One hundred and twelve patients with bladder transitional cell carcinoma were involved in this study. The expression of VEGF, KDR and p53 were evaluated by immunohistochemical staining on paraffin-embedded slides. The correlations between the biomarkers with clinical pathological characteristics were assessed; the co-expression of VEGF and KDR in tumor cells as well as the correlation between p53 and VEGF/KDR expression were analyzed. Results: Expression of VEGF, KDR and p53 was observed in 69.6, 55.4 and 48.2% of TCC patients, respectively. VEGF, KDR and p53 expressions were found to be higher in the invasive bladder tumors than in the superficial tumors, and KDR and p53 expression were significantly associated with higher tumor grade. Co-expression of VEGF and KDR was found in 51 patients, and VEGF expression was associated with KDR expression. Positive correlations were found between p53 protein and VEGF/KDR expression. Conclusion: Our results suggest that VEGF, KDR and p53 might be valuable biomarkers in prognosis of TCC patients. Co-expression of VEGF and KDR implied an autocrine signaling of VEGF in tumor cells, and the results of immunohistochemical staining supported the role of p53 gene in the process of angiogenesis.

Keywords:
Angiogenesis, Vascular endothelial growth factor, Kinase-insert-domain-containing receptor, p53, Transitional cell carcinoma of the bladder
This content is only available via PDF.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.